Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (MACS1755)

This study is currently recruiting participants.

Verified January 2013 by Novartis

Sponsor:

Information provided by (Responsible Party):

Novartis ( Novartis Pharmaceuticals )

ClinicalTrials.gov Identifier:

NCT01478373

First received: November 16, 2011

Last updated: January 24, 2013

Last verified: January 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	December 2013 (Final data collection date for primary outcome measure)